StockNews.AI
TRIN
StockNews.AI
180 days

Trinity Capital Inc. Provides $15 Million in Growth Capital to Cagent Vascular Inc.

1. Trinity Capital commits $15M in growth capital to Cagent Vascular. It supports TRIN's strategic expansion. 2. Cagent Vascular pioneers serration technology for enhanced angioplasty procedures. Clinical evidence spans over 20,000 cases. 3. The move augments previous $45M US Venture Partners equity financing. It underscores TRIN's active role in alternative asset investments.

6m saved
Insight
Article

FAQ

Why Bullish?

The commitment signals TRIN's confidence in high-growth medical technology investments. Past strategic capital infusions in emerging sectors often led to enhanced investor sentiment and upward price movements.

How important is it?

This news enhances TRIN's profile in innovative, growth-oriented investments. While strategically positive, its impact on TRIN's stock price will likely manifest gradually.

Why Long Term?

Investments in pioneering technologies typically take time to mature and generate significant returns. Historical examples in alternative asset management show gradual, sustained positive price movement over extended periods.

Related Companies

TRIN
, /PRNewswire/ -- Trinity Capital Inc. (NASDAQ: TRIN) ("Trinity Capital"), a leading alternative asset manager, today announced the commitment of $15 million in growth capital to Cagent Vascular Inc., a leading developer of serration technology for vessel dilation in endovascular interventions. This capital augments $45 million of equity financing led by US Venture Partners in 2024. Cagent Vascular is a medical device company pioneering innovative vascular treatment technologies. The company's flagship product, Serranator®, helps improve angioplasty procedures by providing more predictable and controlled lumen gain with minimal dissection, while mitigating vessel recoil. Cagent Vascular aims to enhance patient outcomes and advance minimally invasive interventions by developing advanced endovascular solutions. "We are excited to partner with Cagent Vascular as they continue to innovate and expand their platform of valuable solutions for physicians treating patients with peripheral artery disease," said Ryan Kaeding, Managing Director, Life Sciences at Trinity Capital. "Cagent Vascular's Serration technology has been used in over 20,000 procedures and offers a growing library of compelling clinical evidence. We're confident this additional capital will help scale our commercial infrastructure and further accelerate clinical adoption," said Brian Walsh, Chairman and CEO of Cagent Vascular. "Trinity Capital's support is appreciated as we build a leading vascular company and make a difference in the lives of patients around the globe." About Trinity Capital Inc. Trinity Capital Inc. (Nasdaq: TRIN) is an international alternative asset manager, aiming to provide investors with stable and consistent returns through access to the private credit market. We source, vet, and invest in dynamic privately funded growth-oriented companies, giving our investors access to a strong and diversified portfolio. With distinct business verticals, Trinity Capital stands as a trusted partner for innovative companies seeking tailored growth capital solutions. Headquartered in Phoenix, Arizona, the firm has an international footprint, supported by a dedicated team of strategically located investment professionals. For more information, visit the company's website at trinitycapital.com and stay connected by following us on LinkedIn and X (formerly Twitter). About Cagent Vascular Inc. Cagent Vascular Inc., founded and led by serial medical technology entrepreneurs, is the leader in Serration Technology to treat peripheral artery disease. The company has developed a transformative improvement to conventional angioplasty, which is the most commonly performed procedure to restore blood flow. Although angioplasty has been used clinically for over 50 years, there remain significant opportunities to optimize the therapy and to improve the treatment outcomes of cardiovascular disease. To learn more about Cagent Vascular's mission to fight PAD, visit www.cagentvascular.com. SOURCE Trinity Capital Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News